Many series report mortality rates of 5% or less and total complication rate of less than 40-50%.
Surgical mortality less than 3% in high-volume single institutions.
For pancreatic cancer contraindicated with metastases, encasement of the celiac axis, hepatic artery, or superior mesenteric artery, involvement of splenoportal confluence, involvement of the bowel mesentery, and involvement of superior mesenteric vein or portal vein.